Reata Pharmaceuticals (RETA) Expected to Post Earnings of -$0.75 Per Share
Equities analysts forecast that Reata Pharmaceuticals (NASDAQ:RETA) will post earnings per share of ($0.75) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Reata Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.86). Reata Pharmaceuticals posted earnings of ($0.52) per share in the same quarter last year, which indicates a negative year over year growth rate of 44.2%. The firm is scheduled to issue its next quarterly earnings results on Monday, August 13th.
According to Zacks, analysts expect that Reata Pharmaceuticals will report full-year earnings of ($2.14) per share for the current fiscal year, with EPS estimates ranging from ($2.58) to ($1.83). For the next year, analysts forecast that the business will report earnings of ($2.97) per share, with EPS estimates ranging from ($3.82) to ($2.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Reata Pharmaceuticals.
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Tuesday, May 8th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.76. The business had revenue of $32.39 million during the quarter, compared to analyst estimates of $10.21 million.
Reata Pharmaceuticals stock traded up $0.50 during trading hours on Friday, hitting $31.15. The stock had a trading volume of 1,822 shares, compared to its average volume of 207,097. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of -0.12. The company has a market capitalization of $826.47 million, a PE ratio of -15.82 and a beta of 0.10. Reata Pharmaceuticals has a one year low of $30.62 and a one year high of $31.30.
Several institutional investors and hedge funds have recently modified their holdings of RETA. MetLife Investment Advisors LLC bought a new position in shares of Reata Pharmaceuticals during the fourth quarter worth about $127,000. DekaBank Deutsche Girozentrale bought a new position in shares of Reata Pharmaceuticals during the first quarter worth about $152,000. Goldman Sachs Group Inc. bought a new position in shares of Reata Pharmaceuticals during the fourth quarter worth about $307,000. Virtus Fund Advisers LLC bought a new position in shares of Reata Pharmaceuticals during the fourth quarter worth about $394,000. Finally, UBS Group AG increased its holdings in Reata Pharmaceuticals by 473.6% in the first quarter. UBS Group AG now owns 19,933 shares of the company’s stock worth $409,000 after purchasing an additional 16,458 shares in the last quarter. Institutional investors own 49.10% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.